SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) May 1, 2019
SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call Apr 15, 2019
SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens Apr 8, 2019
SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID Apr 3, 2019
SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note Mar 7, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019 Feb 28, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies Jan 30, 2019
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors Jan 22, 2019
